与免疫检查点抑制剂治疗相关的生物标志物

Immune checkpoint inhibitors (ICIs) therapy is an emerging cancer treatment. During treatment it is necessary to monitor the patient at all times and respond to any adverse reactions that may occur, such as immune-related adverse events and unconventional reactions. Biomarkers, the biochemical indicators that mark changes in the structure or function of systems, organs, tissues, and cells, may be used to predict and design treatment for such reactions.

Anti-tumor immunotherapy biomarkers can be derived from the tumors themselves (e. g. negative regulatory molecules and dynamic changes in genome sequence) or from the immune system (e. g. peripheral blood cell population counts, various cytokines, tumor-infiltrating lymphocytes, and intestinal microbes). The development of biomarkers is important for monitoring the effect of treatment, assessing the patient's response to ICIs, determining adverse reactions, and predicting the direction of disease development.

In addition, organ toxicity and systemic events also have an impact on the therapeutic effect of ICIs.